114.01

1.41% 1.58

After Hours: 113.59 -0.42 -0.37%

Abbott Laboratories (ABT)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split Dividend History

Abbott Laboratories stock is traded at $114.01, with a volume of 4.86M. It is up +1.41% in the last 24 hours and up +0.65% over the past month. Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.

Previous Close:

$112.43

Open:

$112.57

24h Volume:

4.86M

Relative Volume:

0.87

Market Cap:

$195.60B

Revenue:

$40.73B

Net Income/Loss:

$5.56B

P/E Ratio:

38.78

EPS:

2.94

Net Cash Flow:

$5.65B

1W Performance:

-0.70%

1M Performance:

+0.65%

6M Performance:

+0.31%

1Y Performance:

+17.72%

1-Day Range:

$112.10

$114.09

1-Week Range:

$111.85

$114.41

52-Week Range:

$89.67

$121.64

Abbott Laboratories Stock (ABT) Company Profile

Name

Abbott Laboratories

Sector

Healthcare (1203)

Industry

Medical Devices (154)

Phone

(224) 667-6100

Address

100 ABBOTT PARK ROAD, ABBOTT PARK, IL

Employee

114,000

Twitter

@AbbottNews

Next Earnings Date

2024-10-16

Latest SEC Filings

ABT's Discussions on Twitter

Abbott Laboratories Stock (ABT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
May-30-24	Initiated	Goldman	Buy
Jul-21-23	Upgrade	Wolfe Research	Underperform → Peer Perform
May-30-23	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Apr-20-23	Reiterated	Barclays	Overweight
Apr-20-23	Reiterated	Bernstein	Outperform
Apr-20-23	Reiterated	JP Morgan	Overweight
Apr-20-23	Reiterated	Raymond James	Outperform
Apr-20-23	Reiterated	UBS	Buy
Apr-20-23	Reiterated	Wolfe Research	Underperform
Mar-29-23	Initiated	UBS	Buy
Oct-26-22	Initiated	Mizuho	Neutral
Oct-18-22	Initiated	Barclays	Overweight
Oct-12-22	Initiated	Jefferies	Hold
Jul-06-22	Initiated	Wolfe Research	Underperform
Mar-02-22	Resumed	BofA Securities	Buy
Jan-27-22	Reiterated	Credit Suisse	Outperform
Jan-27-22	Reiterated	Morgan Stanley	Overweight
Jan-27-22	Reiterated	Raymond James	Outperform
Jan-27-22	Reiterated	UBS	Buy
Dec-10-21	Initiated	RBC Capital Mkts	Outperform
Oct-27-21	Upgrade	Atlantic Equities	Neutral → Overweight
Oct-14-21	Initiated	Redburn	Neutral
May-25-21	Initiated	Barclays	Overweight
Apr-15-21	Initiated	Atlantic Equities	Neutral
Jan-28-21	Upgrade	BTIG Research	Neutral → Buy
Sep-11-20	Initiated	Wolfe Research	Outperform
Jun-01-20	Downgrade	Goldman	Neutral → Sell
Mar-05-20	Initiated	Citigroup	Buy
Feb-13-20	Initiated	Goldman	Neutral
Feb-06-20	Resumed	BTIG Research	Neutral
Jan-02-20	Downgrade	Guggenheim	Buy → Neutral
Jun-13-19	Reiterated	BofA/Merrill	Buy
Feb-07-19	Reiterated	BofA/Merrill	Buy
Jan-02-19	Downgrade	Citigroup	Neutral → Sell
Nov-30-18	Upgrade	Goldman	Neutral → Buy
Oct-16-18	Initiated	Barclays	Overweight
Jun-27-18	Initiated	Bernstein	Outperform
Jan-30-18	Reiterated	Citigroup	Neutral
Jan-25-18	Reiterated	Stifel	Buy
Jan-25-18	Upgrade	William Blair	Mkt Perform → Outperform
Jan-03-18	Initiated	Evercore ISI	Outperform
Jan-02-18	Upgrade	JP Morgan	Neutral → Overweight
Jan-02-18	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Oct-19-17	Reiterated	RBC Capital Mkts	Outperform
Oct-19-17	Reiterated	Stifel	Buy

View All

Abbott Laboratories Stock (ABT) Latest News

04:36 AM

Abbott Laboratories stock outperforms competitors on strong trading day - MarketWatch

04:36 AM

03:44 AM

Abbott, Reckitt trial over infant formula safety starts in Missouri: report (NYSE:ABT) - Seeking Alpha

03:44 AM

02:40 AM

Global Chronic Disease Management Market Size to Reach USD 17.28 Billion by 2033 | Witnessing a CAGR of 12.80% - GlobeNewswire Inc.

02:40 AM

02:36 AM

Abbott Laboratories (NYSE:ABT) Shares Up 0.3% - MarketBeat

02:36 AM

12:15 PM

Second Circuit Affirms Case-Ending Sanctions, Damages Against Defendants in Abbott Diabetes Test Strips Diversion Case - IPWatchdog.com

12:15 PM

12:00 PM

Abbott, Reckitt face trial over premature baby formula amid alarm from doctors - Reuters

12:00 PM

11:24 AM

Jim Cramer sees Abbott becoming a buying opportunity — but says timing is key - CNBC

11:24 AM

08:12 AM

Abbott, Reckitt face trial over premature baby formula amid alarm from doctors By Reuters - Investing.com

08:12 AM

07:43 AM

Abbott Labs (NYSE:ABT) Goes to Trial Over Formula - TipRanks

07:43 AM

05:56 AM

Abbott Laboratories (NYSE:ABT) Shares Sold by Duff & Phelps Investment Management Co. - MarketBeat

05:56 AM

04:49 AM